OriGene Technologies, Inc.
9620 Medical Center Drive, Ste 200
Rockville, MD 20850, US
Phone: +1-888-267-4436
https://www.origene.com
techsupport@origene.com
EU: info-de@origene.com
CN: techsupport@origene.cn

Product datasheet for TA336087

MPG Rabbit Polyclonal Antibody

Product data:

Product Type:	Primary Antibodies
Applications:	WB
Recommended Dilution:	WB
Reactivity:	Human
Host:	Rabbit
Isotype:	IgG
Clonality:	Polyclonal
Immunogen:	The immunogen for Anti-MPG Antibody: synthetic peptide directed towards the C terminal of human MPG. Synthetic peptide located within the following region: LEPSEPAVVAAARVGVGHAGEWARKPLRFYVRGSPWVSVVDRVAEQDTQA
Formulation:	Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose. *Note that this product is shipped as lyophilized powder to China customers.*
Purification:	Affinity Purified
Conjugation:	Unconjugated
Storage:	Store at -20°C as received.
Stability:	Stable for 12 months from date of receipt.
Predicted Protein Size:	32 kDa
Gene Name:	N-methylpurine DNA glycosylase
Database Link:	NP_001015052 Entrez Gene 4350 Human P29372
Background:	MPG functions in the hydrolysis of the deoxyribose N-glycosidic bond to excise 3-methyladenine, and 7-methylguanine from the damaged DNA polymer formed by alkylation lesions.
Synonyms:	AAG; ADPG; anpg; APNG; CRA36.1; MDG; Mid1; PIG11; PIG16
Note:	Immunogen Sequence Homology: Rat: 100%; Human: 100%; Mouse: 100%; Bovine: 85%; Rabbit: 85%; Dog: 79%; Pig: 79%; Horse: 79%; Guinea pig: 79%

View online »

Protein Families: Druggable Genome, Transmembrane

Protein Pathways: Base excision repair

Product images:



WB Suggested Anti-MPG Antibody Titration: 0.2-1 ug/ml; Positive Control: Jurkat cell lysate



WB Suggested Anti-MPG Antibody; Positive Control: Lane 1: 50ug RCC4 lysate, Lane 2: 50ug RCC4 lysate, Lane 3: 50ug 786-0 lysate, Lane 4: 50ug 786-0 lysate; Primary Antibody Dilution: 1: 1000; Secondary Antibody: Anti-rabbit-Alexa 680; Secondry Antibody Dilution: 1: 5000; Submitted by: Dr Ester Hammond, Gray Institute for Radiation Oncology and Biology-Department of Oncology, University of Oxford